clinical trial · NCT06818643
A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)
Merck Sharp & Dohme LLC·phase2·recruiting·n = 270
Advanced Solid TumorsMalignant NeoplasmMK-3120
brief summary
Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.
started
Mar 25, 2025
primary completion
Oct 25, 2028
completion
Mar 25, 2031
last updated
Feb 19, 2026
official title
A Phase 1/2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol